The Investor
31 Aug 2026, 15:52
Eli Lilly Reports Strong One-Year Results for Taltz and Zepbound Combination
Eli Lilly (NYSE: LLY) announced positive 52-week Phase 3b data Monday showing that Taltz and Zepbound used together produced durable improvements in adults with psoriatic disease and obesity.
The results come from the TOGETHER-PsO and TOGETHER-PsA trials, which compared Taltz plus Zepbound with Taltz alone. The combination had already demonstrated statistically superior results at the Week 36 primary endpoint, and Lilly said those improvements were maintained or further strengthened through Week 52.
In the psoriasis trial, 30.6% of patients receiving the combination achieved both complete skin clearance and at least 10% weight loss, compared with 4.4% receiving Taltz alone. Complete skin clearance was achieved by 40.5% of combination-treated patients versus 29.1% with Taltz alone.
Results were also strong in psoriatic arthritis. About 39.2% of patients receiving both drugs achieved at least a 50% improvement in disease activity together with at least 10% weight loss, compared with just 1.7% in the Taltz-only group. The proportion achieving a 50% improvement in disease activity reached 43.7% versus 15.7% with monotherapy.
The combination also produced sustained or improved results across measures including systemic inflammation, BMI, blood pressure, glucose, HbA1c, triglycerides and cholesterol. No new safety concerns were identified, with adverse events generally mild to moderate and consistent with the known profiles of the two medicines.
The findings are significant for Lilly because they suggest Zepbound's role could extend beyond weight management when used alongside established therapies for diseases closely associated with obesity. The data could strengthen the company's position across both the rapidly growing obesity market and immunology, while supporting a broader strategy of treating interconnected metabolic and inflammatory diseases.
Eli Lilly (NYSE: LLY) announced positive 52-week Phase 3b data Monday showing that Taltz and Zepbound used together produced durable improvements in adults with psoriatic disease and obesity.
The results come from the TOGETHER-PsO and TOGETHER-PsA trials, which compared Taltz plus Zepbound with Taltz alone. The combination had already demonstrated statistically superior results at the Week 36 primary endpoint, and Lilly said those improvements were maintained or further strengthened through Week 52.
In the psoriasis trial, 30.6% of patients receiving the combination achieved both complete skin clearance and at least 10% weight loss, compared with 4.4% receiving Taltz alone. Complete skin clearance was achieved by 40.5% of combination-treated patients versus 29.1% with Taltz alone.
Results were also strong in psoriatic arthritis. About 39.2% of patients receiving both drugs achieved at least a 50% improvement in disease activity together with at least 10% weight loss, compared with just 1.7% in the Taltz-only group. The proportion achieving a 50% improvement in disease activity reached 43.7% versus 15.7% with monotherapy.
The combination also produced sustained or improved results across measures including systemic inflammation, BMI, blood pressure, glucose, HbA1c, triglycerides and cholesterol. No new safety concerns were identified, with adverse events generally mild to moderate and consistent with the known profiles of the two medicines.
The findings are significant for Lilly because they suggest Zepbound's role could extend beyond weight management when used alongside established therapies for diseases closely associated with obesity. The data could strengthen the company's position across both the rapidly growing obesity market and immunology, while supporting a broader strategy of treating interconnected metabolic and inflammatory diseases.
